Similarly, 4 years after the initiation of the ARMADA (Anti-TNF Research Study Program of the Monoclonal Antibody D2E7 in Patients with RA) trial, 64% of the 271 enrolled patients were still receiving adalimumab therapy (mean duration of treatment = 3.4 years) [20]. This evidence concerns the gene TNF and rheumatoid arthritis.